Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Acquires $28,842,000.00 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) Director Bros. Advisors Lp Baker purchased 655,500 shares of the firm's stock in a transaction that occurred on Monday, June 30th. The shares were bought at an average price of $44.00 per share, with a total value of $28,842,000.00. Following the acquisition, the director directly owned 6,117,295 shares of the company's stock, valued at $269,160,980. This represents a 12.00% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Kymera Therapeutics Stock Performance

NASDAQ:KYMR traded up $0.80 during trading hours on Tuesday, reaching $44.44. The stock had a trading volume of 1,001,787 shares, compared to its average volume of 630,030. The stock has a market cap of $2.89 billion, a P/E ratio of -14.34 and a beta of 2.18. The stock has a 50 day simple moving average of $37.73 and a 200 day simple moving average of $35.83. Kymera Therapeutics, Inc. has a 12-month low of $19.45 and a 12-month high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings data on Friday, May 9th. The company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.10. Kymera Therapeutics had a negative return on equity of 30.11% and a negative net margin of 409.07%. The company had revenue of $22.10 million during the quarter, compared to analyst estimates of $11.38 million. During the same quarter last year, the firm posted ($0.69) EPS. The firm's revenue for the quarter was up 114.6% on a year-over-year basis. On average, equities analysts expect that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on KYMR. Stifel Nicolaus began coverage on shares of Kymera Therapeutics in a research note on Tuesday, May 20th. They issued a "buy" rating and a $55.00 target price for the company. BTIG Research restated a "buy" rating and set a $59.00 price target on shares of Kymera Therapeutics in a report on Thursday, June 26th. Bank of America upgraded shares of Kymera Therapeutics from a "neutral" rating to a "buy" rating and set a $51.00 price objective for the company in a research note on Monday, June 2nd. Wall Street Zen raised shares of Kymera Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Finally, Oppenheimer reaffirmed an "outperform" rating and issued a $53.00 target price (down from $56.00) on shares of Kymera Therapeutics in a report on Friday. Two equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $59.61.

Hedge Funds Weigh In On Kymera Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KYMR. State of Wyoming purchased a new stake in shares of Kymera Therapeutics in the fourth quarter worth about $45,000. GF Fund Management CO. LTD. purchased a new position in shares of Kymera Therapeutics during the 4th quarter valued at about $55,000. KBC Group NV raised its stake in shares of Kymera Therapeutics by 15.2% during the first quarter. KBC Group NV now owns 2,479 shares of the company's stock worth $68,000 after acquiring an additional 328 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Kymera Therapeutics in the first quarter worth $68,000. Finally, Advisors Asset Management Inc. boosted its holdings in Kymera Therapeutics by 81.7% during the 1st quarter. Advisors Asset Management Inc. now owns 4,959 shares of the company's stock valued at $136,000 after acquiring an additional 2,230 shares during the period.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.